Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome

Not Applicable

Completed

• Conditions: Chronic Fatigue Syndrome
• Interventions: Dietary Supplement: Guanidinoacetic acid; Other: Placebo

• Registration Number: NCT02213679
• Lead Sponsor: Center for Health, Exercise and Sport Sciences, Serbia

Brief Summary

Chronic fatigue syndrome (CFS) is a debilitating condition of unknown etiology. Recent studies have shown that CFS is associated with impaired cellular energetics and low levels of phosphocreatine. Since guanidinoacetic acid (GAA) acts as a highly bioavailable precursor of creatine it may provide an ideal dietary supplement to facilitate treatment and perhaps prevention of CFS. The overall hypothesis to be evaluated is that medium-term supplementation with GAA will improve clinical outcomes in well-defined adult CFS patients via augmented provision of creatine. Specific aims: (1) To determine the effects of GAA on CFS symptomatology using a fatigue severity inventory, soreness of locomotive apparatus scales, and a health-related quality of life survey; (2) To determine the effect of GAA on creatine metabolism using laboratory studies and magnetic resonance spectroscopy; (3) To characterize the physiological effects of GAA on work capacity via actigraphy and exercise performance tests; and (4); To determine the prevalence of subjectively reported side-effects and biochemical adverse events associated with GAA intervention.

Detailed Description

A variety of dietary interventions have been used in the management of CFS, yet no therapeutic modality demonstrated overall positive results in terms of effectiveness (Whiting et al. 2001). Previous studies have evaluated the effects of essential fatty acids, vitamins, minerals and/or enzymes, with findings do not support the use of a broad-spectrum nutritional supplement in treating CFS-related symptoms (Brouwers et al. 2002). Considering the fact that patients with CFS have lower levels of high-energy compounds (e.g. phosphocreatine, adenosine triphosphate) (Block et al. 1998), effective dietary treatment of CFS should be focused on providing compounds that facilitates cellular bioenergetics. Besides other candidate agents, guanidinoacetic acid (GAA) could be of particular interest since it occurs naturally in the human body and acts as an immediate precursor of creatine (Wyss and Kaddurah-Daouk, 2000). Due to its low cost and high bioavailability (Baker 2009), if proven effective dietary GAA may be suitable for use in broad CFS population.

Study Timeline

• Study Start: 2014-08
• Study First Submitted: 2014-08-05
• Study First Submitted QC: 2014-08-07
• Study First Posted: 2014-08-11
• Primary Completion: 2015-06
• Study Completion: 2015-07
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-30
• Last Update Posted: 2017-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Adults who fulfilled the 1994 CDC criteria for CFS
• Older than 18 years of age will be candidates for inclusion in the study.

Exclusion Criteria

• Psychiatric comorbidity
• Use of any dietary supplement within 4-weeks prior to the study commencing
• Pregnant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Guanidinoacetic acid	Guanidinoacetic acid	Supplementation with dietary guanidinoacetic acid
Placebo	Placebo	Supplementation with cellulose

Primary Outcome Measures

Name	Time	Method
Change in the Multidimensional Fatigue Inventory (MFI) score	Baseline and afetr 3 months

Secondary Outcome Measures

Name	Time	Method
Pain in the locomotive apparatus	Baseline and after 3 months

Trial Locations

Locations (1)

Center for Health, Exercise and Sport Sciences; 🇷🇸 Belgrade, Serbia